AACI Commentary

About Our Editorial Series

Exploring Topics of Interest to AACI Cancer Centers

To promote the work of its member centers, AACI publishes Commentary, an editorial series focusing on major issues of common interest to North American cancer centers. 

Each AACI Commentary is written by a cancer center leader or subject matter expert and distributed by email to over 3,500 subscribers of the AACI Update newsletter. 

The publication is designed to cover a specific topic in 750-1,000 words. Recommendations for topics and authors are encouraged. 

Please submit suggestions to: 

Chris Zurawsky
Director of Communications and Public Affairs

Emily Stimmel
Communications and External Relations Manager

January 2022

Promoting Equity by Design in Cancer Trials

By Barbara E. Bierer, MD and Timothy Rebbeck, PhD

Individuals who participate in clinical trials should reflect those who have the disease or condition or, if the epidemiology is not known, the general population. The demographics of patients with cancer do not match the demographics of patients enrolled in cancer treatment trials.

White patients with cancer are overrepresented in clinical research, while other races and ethnicities, particularly Black, Hispanic, and American Indian/Alaska Natives are underrepresented; other often underrepresented groups include women, children and young adults, people with disabilities, and non-English speakers. These groups do not benefit from, nor have equivalent access to, potentially therapeutic clinical research.

As part of a comprehensive effort to address this complex issue, the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard and the Center for Cancer Equity and Engagement at the Dana-Farber/Harvard Cancer Center will offer a six-part virtual course titled "Equity by Design in Clinical Research: Cancer Trials." The curriculum is designed to build on existing knowledge of ethical and regulatory foundations and will highlight key action areas to support inclusion in cancer clinical research. 

Read the January 2022 Commentary.

Promoting Equity by Design in Cancer Trials
By Barbara E. Bierer, MD and Timothy Rebbeck, PhD 
January 2022

AACI and the Early Years of the National Cancer Act
By AACI Staff
December 2021

Reflecting on 50 Years of Progress and Looking Ahead to the Future: Highlights of the 2021 AACI/CCAF Annual Meeting
By Robert A. Winn, MD
November 2021

Leadership Development and Diversity in Cancer Centers
By Caryn Lerman, PhD
October 2021

Confronting Delayed Cancer Screening and Cancer Disparities During the COVID-19 Pandemic
By Chyke A. Doubeni, MBBS, MPH
September 2021

Learning From the Pandemic: Reflections on the 13th Annual AACI CRI Meeting
By Theresa L. Werner
August 2021

A “Delicate Dance”: Establishing a Process for Assessing and Endorsing Cancer-Related Policy
By John DeMuro
July 2021

Engaging Advanced Practice Providers in Cancer Clinical Trials
By Christa Braun-Inglis, MS, APRN-Rx, FNP-BC, AOCNP
June 2021

Harnessing Artificial Intelligence and Emerging Technologies to Enhance Cancer Treatment
By Rohit Bhargava, PhD
May 2021

Who Was First? The National Cancer Act of 1971 and the Birth of NCI-Designated Cancer

By Donald L. Trump, MD, FACP, FASCO and Eric T. Rosenthal
April 2021

The Little State That Could: How West Virginia Became a National Model for COVID-19 Vaccination
By Hannah Hazard-Jenkins, MD, FACS
March 2021

From Pre-Pandemic Politics to a "New Normal": Cancer Policy Priorities for the Biden Presidency
By AACI Staff
February 2021

Sustaining the Use of Telemedicine in Post-Pandemic Cancer Care
By Karen E. Knudsen, MBA, PhD; Cheryl L. Willman, MD; and Robert A. Winn, MD
January 2021